Yahoo Finance

BofA raised the firm’s price target on Hutchmed (HCM) to $27 from $26 and keeps a Buy rating on the shares. While noting it sees “some regulatory headwinds potentially ahead,” the firm keeps a Buy rating on the shares and cites higher revenue expectations for key assets after “strong performance in 2024” for its revised price target

Maximize Your Portfolio with Data Driven Insights:

• Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.

• Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

See Insiders’ Hot Stocks on TipRanks >>

Read More on HCM:

• Hutchmed announces NMPA approval for Orpathys supplemental new drug application

• Hutchmed price target lowered to $26 from $30 at BofA

• Morning Movers: Neumora Therapeutics plummets after KOASTAL-1 misses endpoint

• Hutchmed announces NDA acceptance in China, payment from AstraZeneca

• Hutchmed divests 45% interest in Shanghai Hutchison for $608M